Rhinitis Prevalence and Nasal Respiratory Function of Children and Adolescents with Sickle Cell Disease

Background: Sickle cell disease (SCD) is the most frequent of the hereditary hemoglobinopathies and presents significant morbimortality. Upper respiratory obstruction is a common clinical manifestation in these patients. Objective: To quantify the prevalence of allergic rhinitis (AR) and evaluat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Camila Novais e Silva, Ricardo Reis Dinardi, Cássio da Cunha Ibiapina, Cláudia Ribeiro de Andrade
Formato: article
Lenguaje:EN
PT
Publicado: Sociedade Portuguesa de Pediatria 2021
Materias:
Acceso en línea:https://doaj.org/article/b97181e467ff42f8847596f273fe8bd7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Background: Sickle cell disease (SCD) is the most frequent of the hereditary hemoglobinopathies and presents significant morbimortality. Upper respiratory obstruction is a common clinical manifestation in these patients. Objective: To quantify the prevalence of allergic rhinitis (AR) and evaluate nasal respiratory function in children and adolescents with SCD. Methods: A cross-sectional study was carried out in a reputable Brazilian blood center between July and October 2017. Patients aged between 6 and 18 years with a diagnosis of SCD were included. Measurements for peak nasal inspiratory flow (PNIF), visual analogue scale (VAS) and rhinomanometry were taken. Results: AR was confirmed in 37.4% of the 99-patient sample. Approximately 70% of patients with sickle cell disease and allergic rhinitis were not treated for rhinitis and several were unaware of their diagnosis. Means of 96.6 ± 34.3% of the PNIF predicted value and 0.35 ± 0.21 (Pa / cm3 / s) for rhinomanometry were found. Mean VAS was 4.9 ± 3.2. Conclusion: This study showed a high prevalence of AR in patients with SCD, in addition to significant PNIF and rhinomanometry alterations. Considering the severity of these patients, it is expected that the recognition and treatment of AR will contribute to improved quality of life.